Clinical Social Workers in Rock Springs, WY Accepting Medicare

31 Clinical Social Workers found. Showing 21 - 31

Adam Davies Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1124 College Dr, Rock Springs, WY 82901 Phone: 307-352-6680    Fax: 307-352-6676

Lindy Cobb, PCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1124 College Dr, Rock Springs, WY 82901 Phone: 307-352-6680

David Scott Milam Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Thomas Richard Bibber Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Mona Abood, PCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Charles Michael, PCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Cynthia L Lane, MSW PCSW 226 Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2100 Dewar Drive, Suite 270, Rock Springs, WY 82901 Phone: 307-382-3058

Sarah Johnson Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1471 Dewar Dr Ste 209, Rock Springs, WY 82901 Phone: 307-352-9161

Sondra Ann De La O Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Hilary A Hampton Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Foothill Blvd, Rock Springs, WY 82901 Phone: 307-352-6677

Mr. James Cummings, PSYD, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1471 Dewar Dr Ste 135, Rock Springs, WY 82901 Phone: 307-262-3127

News Archive

Shorter regimen of radiotherapy safe for noninvasive breast cancer patients

Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation Oncology-Biology-Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.

Emdeon, MZIHC enter services agreement

MZI HealthCare, LLC (MZIHC), a leading provider of health plan administration software, announced today that it has entered into a services agreement with Emdeon, a leading provider of revenue and payment cycle management and clinical information exchange solutions.

Study finds abnormal fetal circulation as a risk factor for fetal thrombotic vasculopathy

Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

Read more Medical News

› Verified 4 days ago

• 1
• 2(current)